
This is a corrected version of the article that appeared in print.
Am Fam Physician. 2022;105(6):675-677
Author disclosure: No relevant financial relationships.
Key Points for Practice
• To reduce overall mortality in patients with type 2 diabetes mellitus, the BMJ/MAGIC Group recommends prescribing SGLT-2 inhibitors in those with cardiovascular disease and/or chronic kidney disease or three or more risk factors for cardiovascular disease.
• GLP-1 receptor agonists are reasonable alternatives to SGLT-2 inhibitors in patients with similar risk profiles because this drug class also improves mortality, although to a lesser extent.
• Although SGLT-2 inhibitors and GLP-1 receptor agonists do not increase the risk of severe hypoglycemia, SGLT-2 inhibitors increase the risk of genital infections, and GLP-1 agonists have gastrointestinal adverse effects, especially at initiation and with high doses.
From the AFP Editors
Subscribe
From $145- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available